Introduction
============

Granulocyte-Macrophage Colony-Stimulating Factor (rHuGM-CSF) is used in leucopenic febrile patients to enhance leukocyte production. It can prime resting monocytes and augment their inflammatory response \[[@B1]\]. It strongly up-regulates HLA-DR expression, LPS induced TNF-a monocyte secretion and down-regulates anti-inflammatory cytokines release \[[@B1]\].

Methods
=======

Twenty septic patients, mean age 64.8 ± 3.7 (14 males) and illness severity scoring, SAPS II, 43.5 ± 4.5 were given subcutaneous molgramostin 200 µg q12 h for 3 consecutive days. We observed white blood count increase and PaO~2~/FiO~2~ index course having the same FiO~2~.

Results
=======

WBC count and PaO~2~/FiO~2~ index

  Days   WBC (× 10^3^/mm^3^)   *P* (*t*-test)   PaO~2~/FiO~2~ index   *P* (*t*-test)
  ------ --------------------- ---------------- --------------------- ----------------
  1st    9.72 ± 1.43                            172.8 ± 20.2          
  2nd    15.92 ± 1.83          \< 0.01          199.3 ± 21.8          0.251
  3rd    30.81 ± 419           \< 0.01          167.6 ± 23.8          0.478
  4th    19.20 ± 1.44          \< 0.01          193.6 ± 20.9          0.392

There was a statistically significant increase in WBC count between the 1st and 2nd, 3rd and 4th days (*P* \< 0.01). There was no statistically significant PaO~2~/FiO~2~ index improvement between the 1st, 2nd and 4th days (*P* \< 0.251 and 0.392) and index deterioration between the 1st and 3rd day (*P* \< 0.478).

Conclusions
===========

Despite significant WBC count increase after rHu GM-CSF supplementation, the PaO~2~/FiO~2~ index was not significantly altered. Molgramostin, when given in septic patients may improve the PaO~2~/FiO~2~ index except during the 3rd day of the major WBC count increase during which there is a nonstatistically significant decrease in this index by 3.1%. GM-CSF supplementation can be safely used without deteriorating pulmonary gas exchange function.
